Approach could also be applied to reversing aging and age-related diseases such as hearing loss and macular degeneration
Salk scientists have created a new version of the CRISPR/Cas9 genome editing technology that allows them to activate genes without creating breaks in the DNA, potentially circumventing a major hurdle to using gene editing technologies to treat human diseases.
“Although many studies have demonstrated that CRISPR/Cas9 can be applied as a powerful tool for gene therapy, there are growing concerns regarding unwanted mutations generated by the double-strand breaks through this technology,” says Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory and senior author of the new paper, published in Cell on December 7, 2017. “We were able to get around that concern.”
In the original CRISPR/Cas9 system, the enzyme Cas9 is coupled with guide RNAs that target it to the right spot in the genome to create DSBs. Recently, some researchers have started using a “dead” form of Cas9 (dCas9), which can still target specific places in the genome, but no longer cuts DNA. Instead, dCas9 has been coupled with transcriptional activation domains—molecular switches—that turn on targeted genes. But the resulting protein—dCas9 attached to the activator switches—is too large and bulky to fit into the vehicle typically used to deliver these kinds of therapies to cells in living organisms, namely adeno-associated viruses (AAVs). The lack of an efficient delivery system makes it very difficult to use this tool in clinical applications.
Izpisua Belmonte’s team combined Cas9/dCas9 with a range of different activator switches to uncover a combination that worked even when the proteins were not fused to one another. In other words, Cas9 or dCas9 was packaged into one AAV, and the switches and guide RNAs were packaged into another. They also optimized the guide RNAs to make sure all the pieces ended up at the desired place in the genome, and that the targeted gene was strongly activated.
“The components all work together in the organism to influence endogenous genes,” says Hsin-Kai (Ken) Liao, a staff researcher in the Izpisua Belmonte lab and co–first author of the new paper. In this way, the technology operates epigenetically, meaning it influences gene activity without changing the DNA sequence.
To test the method, the researchers used mouse models of acute kidney injury, type 1 diabetes and a form of muscular dystrophy. In each case, they engineered their CRISPR/Cas9 system to boost the expression of an endogenous gene that could potentially reverse disease symptoms. In the case of kidney disease, they activated two genes known to be involved in kidney function, and observed not only increased levels of the proteins associated with those genes, but improved kidney function following an acute injury. For type 1 diabetes, they aimed to boost the activity of genes that could generate insulin-producing cells. Once again, the treatment worked, lowering blood glucose levels in a mouse model of diabetes. For muscular dystrophy, the researchers expressed genes that have been previously shown to reverse disease symptoms, including one particularly large gene that cannot easily be delivered via traditional virus-mediated gene therapies.
“We were very excited when we saw the results in mice,” adds Fumiyuki Hatanaka, a research associate in the lab and co–first author of the paper. “We can induce gene activation and at the same time see physiological changes.”
Izpisua Belmonte’s team is now working to improve the specificity of their system and to apply it to more cell types and organs to treat a wider range of human diseases, as well as to rejuvenate specific organs and to reverse the aging process and age-related conditions such as hearing loss and macular degeneration. More safety tests will be needed before human trials, they say.
The Latest on: CRISPR/Cas9 genome editing technology
- Scientists created a new tomato variety by editing the genome of a wild plant on October 2, 2018 at 10:10 am
RELATED Speed breeding breakthrough to boost crop research In an effort to solve the problems associated with over-breeding, scientists turned to the gene editing technology CRISPR-Cas9. Researchers u... […]
- UCSB Researchers Create a New Genome Editing Method on September 27, 2018 at 8:54 am
Genetic engineering has made tremendous leaps in the past few years thanks to revolutionary technologies like CRISPR-Cas9, which allows scientists ... new method of infrared light-triggered genome edi... […]
- Roundtable on “Genome Editing: Why Ethics Matter?” on September 24, 2018 at 10:14 am
At the heart of the discussions was a new genome “editing” technique called CRISPR-Cas9. This technique makes it possible ... Sports, Science and Technology of Japan, the event welcomed Dr. Peter Mill... […]
- Intellia Therapeutics (NTLA) Educational Briefing On Interference Proceedings Relating To CRISPR/Cas9 Genome Editing Technology Patents - Slideshow on August 29, 2018 at 10:05 am
The following slide deck was published by Intellia Therapeutics in conjunction with this event. 124 Click to enlarge Notes: The following slide deck was published by Intellia Therapeutics in conjuncti... […]
- Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer on August 8, 2018 at 5:49 am
August 08, 2018 08:30 ET | Source: Yield10 Bioscience, Inc. WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create ste... […]
- Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer on August 7, 2018 at 5:00 pm
WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security ... […]
- CRISPR/Cas9 gene editing scissors are less accurate than we thought, but there are fixes on July 16, 2018 at 1:15 pm
CRISPR gene editing technology is revolutionising medicine and biology ... Cas9 recognises a specific segment of DNA among the entire human genome by utilising a guide, something like a map, that is l... […]
- Genome damage from CRISPR/Cas9 gene editing higher than thought on July 16, 2018 at 8:00 am
CRISPR/Cas9 is one of the newest genome editing tools. It can alter sections of DNA in cells ... It is important that anyone thinking of using this technology for gene therapy proceeds with caution, a... […]
- Syngenta obtains non-exclusive IP license from Broad Institute for CRISPR-Cas9 genome-editing technology for agriculture applications on November 1, 2017 at 5:00 pm
Syngenta announced today it has attained a non-exclusive IP license from the Broad Institute of MIT and Harvard for CRISPR-Cas9 genome-editing technology for agricultural applications. CRISPR-Cas9 gen... […]
- Genome Editing with CRISPR-Cas9 Prevents Angiogenesis of the Retina on July 24, 2017 at 2:05 pm
In a report published online today in Nature Communications, the researchers present a novel gene-editing technique ... to impaired vision. CRISPR-Cas9 is a powerful new technology that can target and ... […]
via Google News and Bing News